In the lysosomal storage disorder Gaucher disease (GD), glucosylceramide (GlcCer) accumulates due to the defective activity of glucocerebrosidase. A subset of GD patients develops neuropathology. We now show mislocalization of Limp2-positive puncta and a large reduction in the number of Lamp1-positive puncta, which are associated with impaired tubulin. These changes occur at an early stage in animal models of GD, prior to development of overt symptoms and considerably earlier than neuronal loss. Altered lysosomal localization and cytoskeleton disruption precede the neuroinflammatory pathways, axonal dystrophy and neuronal loss previously characterized in neuronal forms of GD.
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Keywords: Gaucher disease; glucosylceramide; lysosomes; neurons; neuropathology; paclitaxel Gaucher disease (GD) is a recessive, inherited disorder caused by mutations in GBA1, which causes deficiency of the lysosomal hydrolase glucosylceramidase (GCase), resulting in accumulation of glucosylceramide (GlcCer) and glucosylsphingosine [1] . GD is classically divided into three clinical subtypes based on age of onset and on signs of nervous system involvement, with the neurological forms neuronopathic GD (nGD), types 2 (acute) and 3 (chronic), displaying central nervous system involvement in addition to systemic disease. The recently discovered genetic association between GBA1 mutations and Parkinson's disease [2] has significantly enhanced the visibility of nGD research.
The most consistent neuropathological finding reported in human nGD patients is accumulation of lipid-laden macrophages as well as neuronal loss and neuroinflammation [3] . The use of mouse models of nGD [4] [5] [6] has resulted in the discovery of additional pathways involved in neuropathology, such as neuronal loss [7] , neuroinflammation [8] and activation of specific signaling pathways [9, 10] . The Gba flox/flox ; nestin-Cre mice [4] , a commonly used nGD mouse model, exhibits rapid motor dysfunction associated with severe neuroinflammation and neuronal loss starting at 14 days of age, and develops paralysis by 21 days. Microarray analysis revealed that by day 14,~10% of genes were differentially expressed in the brain.
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Thus, significant changes in gene expression and in neuroinflammation only begin at 14 days of age in Gba flox/flox ;nestin-Cre mice, although GlcCer and glucosylsphingosine levels were elevated two-to threefold by 10 days of age [8] .
We now examine whether activation of any cellular pathways occurs before neuronal loss and microglia activation. We demonstrate mislocalization of Limp2-positive puncta in neurons and loss of Lamp1-labeled puncta, which is associated with cytoskeletal impairment. We suggest that lysosomal mislocalization and dysfunction might be primary events that precede overt neuropathology in nGD, and possibly in other lysosomal storage disorders (LSDs).
Materials and methods

Animals
Various strains of mice were used: (a) Gba flox/flox ;nestin-Cre mice, which were generated by crossing Gba flox/flox mice with Gba flox/WT ;nestin-Cre mice; heterozygous Gba flox/WT ;nestinCre mice served as healthy controls [4] . Gba flox/flox ;nestinCre mice live for~21-28 days, and have been well characterized in terms of the development of neuronal pathology [7, 11] . (b) Mice with a mixed genetic background (C57BL6/J and CBA with further back-crossings with C57BL6/J; Jackson Laboratories, Sacramento, CA, USA), which express Thy1-YFP-H in specific subsets of neurons, including pyramidal neurons of cortical layer V [12] . These mice were injected intraperitoneally with conduritol b-epoxide (CBE) (Calbiochem Millipore, Darmstadt, Germany), a GCase inhibitor. CBE has been used to induce GD in various mouse strains [13] , and the pathology is remarkably similar to that observed in Gba flox/flox ;nestin-Cre mice [5] . Genotyping was performed by polymerase chain reaction (PCR) using genomic DNA extracted from mouse tails. Mice were maintained in the experimental animal center of the Weizmann Institute of Science. Pregnant HsdOla:WIST rats (Envigo, Jerusalem, Israel) were used for primary cortical neuron isolation. All animal experiments were approved by the Weizmann Institute Institutional Animal Care and Use Committee.
Gene expression profiling microarray analysis
Gene expression profiling microarray analysis was performed as described [9] , but using RNA from the VPM/ VPL region of Gba flox/WT ;nestin-Cre mice and Gba flox/flox ; nestin-Cre mice at 10 days of age.
Immunofluorescence
Brains were removed and immersion fixed in 4% paraformaldehyde in 0. 
Neuronal cultures
Cortical neurons were cultured from embryonic day 16-17 HsdOla:WIST rats. Cortices were dissociated by trypsinization (0.25%, w/v, 15 min, 37°C). The tissue was washed in Mg/Ca-free Hank's balanced salt solution (Gibco, North Andover, MA, USA) and dissociated by repeated passage through a constricted Pasteur pipette. Cells were plated in glial minimal essential medium (Beit Haemek) with 10% horse serum and Glutamax (Gibco) at a density of either 5 9 10 3 cells per 35 mm Petri dish (with a glass bottom for live imaging (Greiner bio-one, Monroe, NC, USA) or at 2 9 10 5 cells per 60 mm Petri dish (Nunc, Roskilde, Denmark) on a microscope cover glass that had been precoated with poly-L-lysine (1 mgÁmL À1 ). After 3-4 h, the medium was changed to Neurobasal medium containing B27 supplement (Gibco) and Glutamax. Cultures were maintained at 37°C in an atmosphere containing 5% CO2. To prevent proliferation of non-neuronal cells, 5 lM cytosine arabinoside (Sigma, St. Louis, MO, USA) was added 2-3 days after plating. For immunofluorescence, neurons cultured on cover slips were fixed with 4% paraformaldehyde followed by blocking with 4% bovine serum albumin (Sigma) and 0.03% Triton X-100. Coverslips were then incubated with either a mixture of anti-b-III tubulin (1 : 500, Abcam) together with anti-Limp2 (rabbit, polyclonal 1 : 500, Novus Biologicals), anti-Lamp1 
Microtubule regrowth assay
Cortical neurons were plated on coverslips and grown for 7 days with or without 400 lM CBE. Microtubules were depolymerized in 5 lM nocodazole in neurobasal medium for 90 min at 37°C and then washed with neurobasal medium and incubated at 37°C to allow regrowth [14] . Cells were fixed with 4% paraformaldehyde and immunolabeled with an antibody to acetylated tubulin (1 : 500 mouse monoclonal, Santa Cruz, CA, USA). The amount of acetylated tubulin on the cover slip was quantified using IMAGEJ software (NIH, Bethesda, MD, USA). 
Electron microscopy
YFP labeling
Thy1-YFP-H mouse brains were removed and free-floating slices (30 lm coronal sections) were prepared using a sliding microtome (Leica Biosystems, Nussloch, Germany). Slices were stored as described [7] and mounted on slides before analysis.
Results
Lysosome mislocalization in nGD neurons
In order to detect cellular pathways that precede previously observed neuropathological changes, such as neuronal loss [7] and neuroinflammation [8] , we first analyzed changes in gene expression in the ventral posteromedial/posterolateral (VPM/VPL) region of the thalamus of Gba flox/flox ;nestin-Cre mice at 10 days of age, an age at which no overt pathology is detected [7] . Consistent with the lack of overt pathology, no changes (fold-change ≥ 1.5, P value ≤ 0.05) in gene To determine whether GlcCer accumulation results in any cellular changes in 10-day-old Gba flox/flox ;nestin-Cre mice, brain sections were labeled with an antibody to lysosomal integral membrane protein 2 (Limp2), a lysosomal sorting receptor that directs GCase to the lysosome [15] . Altered distribution of Limp2-labeled puncta was detected, with generation of several large vesicles and linear structures (Fig. 1) in layer V of the cortex as early as day 8, and gradually extended to other areas such as layer II of the cortex and the hippocampus at 16 days of age ( Fig. 2A) . In contrast, labeling with an antibody to lysosomal-associated membrane protein (Lamp1), a protein that maintains the structural integrity of lysosomes [16] , showed a different distribution, with no linear structures or large vesicles, although the number of Lamp1-positive vesicles in layer V of the cortex was significantly decreased to about half of that found in control neurons by day 12 (Fig. 1B) . The subcellular localization of these structures was examined in Thy1-YFP-H mice in which nGD was induced by daily i.p. injection of CBE. Limp2-positive vesicles were located near the nucleus and extended into neurites (Fig. 2B) , in contrast to control cells, where a typical lysosomal distribution was observed (Fig. 2B) . In contrast, this altered pattern of Limp2-positive puncta was not observed in neurons from another LSD mouse model, Niemann Pick C (NPC) (not shown), at 7 weeks of age, a stage in which overt pathology is already seen [17] .
To determine whether changes in the localization of Limp2-positive structures was cell autonomous, we examined their distribution in cultured cortical neurons incubated with 400 lM CBE for 9 days, a time at which significant levels of GlcCer accumulate [18] . Perinuclear Limp2-positive puncta were observed in neurites from approximately half (47.5 AE 4.8%, n = 3) of the neurons treated with CBE (Fig. 3A,  Fig. S1 ), whereas no change was observed in the distribution of Lamp1-positve puncta, although Lamp1 was found in a more diffuse pattern (Fig. 3B) . Moreover, no change was observed in the acidic nature of the lysosome as determined by labeling with Lysotracker (Fig. 3C) , suggesting that the lysosomal membrane is still intact.
Electron microscopy of neurons treated with CBE revealed aggregation of enlarged vesicles containing lamellated membranes (Fig. 4A-C) , presumably lysosomes, in the cell body and proximal part of the neurite, sometimes adjacent to the neurite membrane; no such distribution was seen in control neurons. These vesicles appeared unaltered in the distal part of the axon (Fig. 4B) . Together, these data suggest that changes in the localization of Limp2-positive vesicles are cell autonomous and an early event in nGD pathology. This appears unique to Limp2-positive vesicles since no change in labeling pattern was observed using an anti-rab5 antibody (early endosomes) or using mitotracker to label mitochondria (not shown).
Microtubule destabilization and axonal degeneration
Mislocalization of lysosomes or impairment of anterograde transport of organelles can result from cytoskeletal damage [19] . This was examined by microtubule regrowth experiments [14] in cultured cortical neurons incubated with CBE. After regrowth for 1 min, few if any microtubules were detected in neurons incubated with CBE whereas in untreated neurons, microtubules regrew and appeared similar to neurons that were not treated with the depolymerizing agent (Fig 5A,B) . However, by 5 min of regrowth, microtubules appeared similar in both CBE-treated and control neurons (Fig 5A,B) . Next, paclitaxel, a drug that interferes with microtubules dynamics and stabilizes them [20] was administered to CBE-treated neurons to examine if stabilization of microtubules influences lysosomal distribution. A significant reduction in the percent of cells exhibiting mislocalization of Limp2-positive vesicles was observed in CBE-treated cells that were given paclitaxel (Fig. 5C ). This suggests that cytoskeletal impairment precedes and/or may result in altered lysosomal localization, or that enhanced microtubule stability may interfere with the primary lysosomal defect.
Impaired tubulin is also associated with a mechanism of axonal degeneration known as 'dying-back' neuropathy [21] , in which the distal part of the axon degenerates first, with axonal atrophy advancing slowly towards the cell body. To examine whether such a mechanism occurs in nGD, and whether this might be associated with impaired microtubules, CBE was injected into Thy1-YFP-H mice, a mouse that expresses YFP in cortical layer V neurons [12] . In brains from CBE-treated mice, spheroids (defined as swellings of neurites that are typically used as a signature of axonal dystrophy [22, 23] ) were observed along the length of the neurites, while no spheroids were detected in control mice injected with PBS (Fig. 6A) . Axonal spheroids appeared initially in the distal region of the axons and only later in the proximal region (Fig. 6B ). Neurons were negative for Fluoro-Jade staining, suggesting that there is no neuronal death at the time when axons start to degenerate. As predicted, the alteration in the localization of Limp2-positive lysosomes preceded the generation of spheroids (Fig. 6C) and neuronal cell death.
Discussion
In the current study, we show that the first detectable pathological event in neuronal models of nGD is the appearance of perinuclear Limp2-positive vesicles, which can be detected prior to changes in gene expression and prior to any overt symptoms. Presumably, the change in distribution of Limp2-positive vesicles is a result of GlcCer accumulation, since 2 days after the first appearance of these vesicles, GlcCer levels increased by~3-fold [11] .
Unexpectedly, similar changes were not observed with other lysosomal markers such as Lamp1. This may be related to the role of Limp2 as a lysosomal sorting receptor for GCase [15] . Lysosomal subsets containing different subclasses of lysosomal proteins might exist, as has been suggested in other LSDs [24] [25] [26] , including Niemann Pick disease in which NPC1 is localized in a subset of Lamp2-positive vesicles [27] . Despite the lack of mechanistic clarity concerning the mislocalization of Limp2-positive vesicles, this phenomenon appears to be related to cytoskeletal stability, which has been previously observed upon GlcCer accumulation in GBA2 null mice [28] , in which extralysosomal GlcCer accumulates and alters cytoskeletal dynamics due to a more ordered lipid environment in the plasma membrane; however, in GD, GlcCer can escape from lysosomes and affect processes that occur in the endoplasmic reticulum [29] . Alternatively, increasing cytoskeletal stability reduced the percentage of cells exhibiting pathology, suggesting that it precedes and/or may result in altered lysosomal localization. However, we cannot exclude the possibility that impaired cytoskeletal dynamics is not the direct cause of pathology, and that increasing the stability of microtubules merely interferes with the aberrant distribution of lysosomes. The latter is supported by the observation that not all lysosomes are affected, suggesting that there is no general impairment in organelle trafficking, at least not at an early stage. This means that mislocalization of lysosomes and the impaired cytoskeleton might be a co-occurring but not functionally related event. We cannot determine whether impaired cytoskeletal stability or altered organelle trafficking leads to the mislocalization of Limp2-positive vesicles, but it should be noted that vesicles containing high GlcCer levels tend to fuse with each other [30] .
In addition to studying the mislocalization of lysosomes, we also documented the spatiotemporal progression of brain pathology in nGD, with pathology first detected in layer V of the cortex [7] . A similar pattern is seen in hereditary spastic paraplegia (HSP), a family of disorders which primarily result from abnormal membrane trafficking. In HSP, long nerves are mainly affected since they have to transport cellular material over long distances [31] , thus they are the most sensitive to impaired membrane trafficking. As in HSP, it is possible that layer V neurons are the first to be affected since they are the longest cells in the cortex [32] . It is not known whether mislocalized lysosomes are found in HSP, but our data is consistent with the notion that altered membrane trafficking due to cytoskeletal abnormalities might be an early event in various neurodegenerative diseases, similar to that observed in Krabbe disease [33] .
